cannabis stocks
cannabis stocks · page 3
- Clinical Research
Evidence, Earnings and Expansion: Avextra Enrolls its First Patient to Landmark Italian Clinical Trial, as Market Leaders Wrangle to Maintain Dominance
The European medical cannabis industry is continuing to mature, seeing companies focused on science-based research push the boundaries of our understanding of its use cases, and more importantly, fill the long-maligned gap in clinical evidence.
- Industry Trends
Speculation to Selectivity: Renewed Optimism Emerges Across Cannabis and Biotech Plays
Tilray Tilray has enjoyed a series of significant bumps in stock price over the last couple of weeks, driven largely by last week’s fervent speculation over the President’s social media posts.
- Investment & Finance
Trump Sends Cannabis Stocks Surging, Cantourage Brings in Investor Relations Help, & Mamedica Secures £4.5m
Cannabis Stocks Surge on Trump Video Global cannabis stocks have enjoyed a considerable, but likely temporary, run this week, after US President Donald Trump shared a video apparently endorsing the use of CBD for senior healthcare.
- Public Markets
Cannabis Stocks Hit Highest Point This Year on Trump Rescheduling Hopes
Cannabis stocks across North America have skyrocketed to their highest point so far this year, despite a lukewarm promise from the US President on cannabis rescheduling.
- Uncategorized
Tilray & Flora Growth Target Stock Consolidation as Values Continue Decline, Chill Brands Raises £1m From Major Shareholder
Tilray [stock_market_widget type=”chart” template=”line” assets=”TLRY” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] The international cannabis giant has announced plans to issue a ‘reverse stock split’, an increasingly common tool in the cannabis industry to artificially inflate stock prices.
- Uncategorized
Ananda Lists on US OTCQB Market, Argent Bio Signs Data Sharing Deal With AusCann, & IMC Under New Threat of NASDAQ Delisting
Ananda Pharma [stock_market_widget type=”chart” template=”line” assets=”ANANF” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Just days after welcoming the former Chief Operating Officer of GW and Jazz Pharmaceuticals to its ranks Ananda has announced its entrance onto the US OTCQB Exchange, opening up its stock to US investors.
- Markets & Stocks
Ananda Gets Ethics Approval for Australian Clinical Study, Synbiotic Launches Germany’s First THC-Pastille, & More from Stenocare
UK-based cannabinoid pharmaceutical company Ananda Pharma has received ethics approval for a Phase 1 clinical study for its lead compound in Australia.
- Markets & Stocks
Akanda Sells UK’s Canmart as it Pivots Away From Cannabis, Argent Bio Seeks Deals for Malta Facility, & Chill Brands to Raise £1m
Akanda [stock_market_widget type=”chart” template=”line” assets=”AKAN” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Akanda Corp has become the latest listed cannabis company to announce its (partial) exit from the industry as it pivots from medical cannabis cultivation in Europe to telecommunications in South America.
- Adult-Use
Federal Cannabis Legalization Proposal to Be Submitted by End of the Week as US Stocks Rise
A proposal for federal legalization of cannabis is now expected to be submitted to the White House by the end of the week, driving a bump in US cannabis stocks.
- Uncategorized
Cannabis Stocks Fall as DEA Ordered to Respond to Bias Allegations
Cannabis stocks plummeted this week after a judge ordered the Drug Enforcement Agency (DEA) to respond to damning new allegations that it is working to undermine the cannabis rescheduling process.
- Markets & Stocks
Tilray Wins Tender to Supply Luxembourg, Argent Biopharma Completes Capital Raise, & More from Stenocare
Argent BioPharma [stock_market_widget type=”chart” template=”line” assets=”RGT.AX” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Argent Biopharma (previously MGC Pharmaceuticals) has completed a US$4.5 million capital raise to support its drug development efforts, just weeks after delisting from the London Stock Exchange.
- Markets & Stocks
Ananda Announces Phase 1 Clinical Trial in Australia, Hellenic Suffers Further Funding Delays, & Flora Expands Reach in Germany
Hellenic Dynamics Hellenic Dynamics has announced a further delay in the receipt of a long-term €1m loan, which has already led to the delay in the publication of its full-year results and the suspension of its shares.
